XML 31 R17.htm IDEA: XBRL DOCUMENT

Collaboration Agreements (Tables)

3 Months Ended

Mar. 31, 2017

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Japan Agreement were as follows (in thousands):

		Three Months Ended March 31,
Agreement	Deliverable	2017		2016
Japan	License	$	212	$	75
	Milestones		—		—
	Total license and milestone revenue		212	$	75
	Collaboration services revenue*		11	$	4

When and if available compounds, manufacturing — clinical supplies and committee services have each been identified as separate units of accounting with standalone value and amounts allocable to these elements have been recognized and classified within the Collaboration services revenue line item within the condensed consolidated statements of operations.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through March 31, 2017		Deferred Revenue at March 31, 2017		Total Consideration Through March 31, 2017
License	$	45,922	$	—	$	45,922
When and if available compounds		22		25		47
Manufacturing--clinical supplies		2,131		—		2,131
Committee services		20		—		20
Total license and collaboration services revenue	$	48,095	$	25	$	48,120

Europe [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Europe Agreement were as follows (in thousands):

		Three Months Ended March 31,
Agreement	Deliverable	2017		2016
Europe	License	$	3,037	$	3,238
	Milestones		—		—
	Total license and milestone revenue		3,037		3,238
	Collaboration services revenue*	$	329	$	348

When and if available compounds, manufacturing — clinical supplies, development services — in progress at the time of signing of the agreement, and committee services have each been identified as a separate unit of accounting with standalone value and amounts allocable to these units have been recognized in revenue as services are performed and classified within the Collaboration services revenue line item within the condensed consolidated statements of operations.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the Europe Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through March 31, 2017		Deferred Revenue at March 31, 2017		Total Consideration Through March 31, 2017
License	$	415,309	$	—	$	415,309
When and if available compounds		387		404		791
Manufacturing--clinical supplies		9,948		—		9,948
Development services--in progress		33,275		—		33,275
Committee services		287		—		287
Total license and collaboration services revenue	$	459,206	$	404	$	459,610

U.S./RoW [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the U.S./RoW Agreement were as follows (in thousands):

		Three Months Ended March 31,
Agreement	Deliverable	2017		2016
U.S. / RoW and China	License	$	16,332	$	16,425
	Milestones		—		—
	Total license and milestone revenue		16,332		16,425
	Collaboration services revenue*		6,970		8,184
	China single unit of accounting**	$	—	$	—

Co-development, information sharing, and committee services have been combined into a single unit of accounting because the requirements to share information and serve on committees are useful only in combination with the development services, and because all three items are delivered over the same period while manufacturing — clinical supplies has been identified as a separate unit of accounting with standalone value and amounts allocable to this unit of accounting have been recognized and classified within the Collaboration services revenue line item within the condensed consolidated statements of operations.

All revenues attributable to the China unit of accounting are deferred until all deliverables are met. The China license and collaboration services elements have been combined into a single unit of accounting and consideration allocable to this unit is being deferred due to FibroGen’s retention of manufacturing rights and lack of standalone value.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the U.S./RoW Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through March 31, 2017		Deferred Revenue at March 31, 2017		Total Consideration Through March 31, 2017
License	$	419,029	$	—	$	419,029
Co-development, information sharing & committee services		97,719		29,680		127,399
Manufacturing--clinical supplies		383		53		436
China-single unit of accounting		—		85,890		85,890
Total license and collaboration services revenue	$	517,131	$	115,623	$	632,754